Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06054217 · ClinicalTrials.gov registry record · Phase 2
Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex
A Phase 2 study of Meibomian Gland Dysfunction and Blepharitis, sponsored by Tarsus Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 2
- Study locations
NCT06054217: Active Phase 2 study of Meibomian Gland Dysfunction and Blepharitis, sponsored by Tarsus Pharmaceuticals.
NCT06054217 is a Phase 2 study of Meibomian Gland Dysfunction and Blepharitis that is active but no longer recruiting, run by Tarsus Pharmaceuticals. The registered enrollment target is 36 participants, below the 98-participant average among 8 other Meibomian Gland Dysfunction trials with a reported enrollment target (63% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06054217, a Phase 2 study of Meibomian Gland Dysfunction and Blepharitis, is active but no longer recruiting, sponsored by Tarsus Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate and compare the effect of two dosing regimens, BID versus TID dosing, of an Exploratory Vehicle (EV) on meibomian gland dysfunction (MGD) in patients with Demodex lid infestation.
Conditions Studied
Interventions
- DRUG Vehicle of TP-03
Study Locations (2)
California
- Shultz Chang Vision - Northridge
North Carolina
- Vita Eye Clinic - Shelby
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2024-06-15 |
| Phase | Phase 2 |
What the registry record for NCT06054217 still lists
NCT06054217 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 98-participant average among 8 other Meibomian Gland Dysfunction trials with a reported enrollment target (63% lower).
The record links to 4 conditions, with Meibomian Gland Dysfunction appearing as the primary indexed condition, and to 1 intervention - of which Vehicle of TP-03 is the first listed.
NCT06054217 reports a single indexed study location in California, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06054217 about?
NCT06054217 is a clinical study titled "Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex". The purpose of this study is to evaluate and compare the effect of two dosing regimens, BID versus TID dosing, of an Exploratory Vehicle (EV) on meibomian gland dysfunction (MGD) in patients with Demodex lid infestation.
What is the current status of trial NCT06054217?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2023-08-01. Estimated completion is 2024-06-15.
What conditions does trial NCT06054217 study?
This clinical trial studies the following conditions: Meibomian Gland Dysfunction, Blepharitis, Demodex Infestation of Eyelid, Demodectic Blepharitis.
What interventions are being tested in trial NCT06054217?
The interventions under investigation include: Vehicle of TP-03 (DRUG).
Who is sponsoring clinical trial NCT06054217?
This trial is sponsored by Tarsus Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06054217 being conducted?
This trial has 2 study locations across California, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Meibomian Gland Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06054217's enrollment target sits among peer trials
36 7th of 8 higher than 2 of 8 other Meibomian Gland Dysfunction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Meibomian Gland Dysfunction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Meibomian Gland Dysfunction Management
ACTIVE NOT RECRUITING · NA
-
Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD
ACTIVE NOT RECRUITING · NA
-
Comparison Between iLux™ and LipiFlow® in the Treatment of Meibomian Gland Dysfunction
COMPLETED · NA
-
The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction
COMPLETED · NA
-
Comparison Between iLux and LipiFlow in the Treatment of Meibomian Gland Dysfunction (MGD): A 12-month, Multicenter Study
COMPLETED · NA
-
Clinical Study Using Eye Lipid Mobilizer (ELM) With Heat and Vibration To Treat Evaporative Dry Eye Disease
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI